Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STI-2020dna
- Development stage
- Preclinical
- Lead developer
- Sorrento Therapeutics
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
STI-2020dna is a gene therapy developed by Sorrento Therapeutics, following its acquisition of SmartPharm Therapeutics. This drug is a DNA plasmid designed to encode and deliver Sorrento's STI-1499 antibody. Utilizing SmartPharm's non-viral gene delivery platform, STI-2020dna aims to enable the patient's body to produce its own neutralizing antibodies internally for extended periods, primarily targeting COVID-19. The technology is also intended for future applications in cancer and rare diseases, offering a potentially cost-effective and long-lasting therapeutic or prophylactic approach.
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on STI-2020dna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STI-2020dna.